drugset
drugset / Trial / NCT04249622

Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer

NCT04249622 ↗

Phase 2 Terminated 20 enrolled Mayo Clinic
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This phase II trial studies how well rifaximin works for the treatment of gastrointestinal toxicities related to pertuzumab-based therapy in patients with stage I-III HER2 positive breast cancer. Rifaximin may reduce the incidence and severity of pertuzumab induced gastrointestinal toxicities without interrupting or delaying the chemotherapy schedule.

Timeline

Start
2020-09-18
Primary completion
2022-12-27
Completion
2022-12-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifaximin Other / unclassified — Oral

Indications

HER2 positive breast carcinoma